GlassScriptPhysician profile
Peter Andrews
NPI 1316984255
$14,108.34
in general payments reported to CMS, 2019-2025
27 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 77% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,980 · 2020: $299 · 2021: $859 · 2022: $1,171 · 2023: $4,999 · 2024: $1,537 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191 · Consulting Fee: $3,000 · Travel and Lodging: $590 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.65 |
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $590.24 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $4,478.16 | 2019-2025 | |
| Alcon Vision LLC | $2,811.28 | 2019-2025 | Clareon, Wavelight Refractive Suite, Contoura Vision |
| Johnson & Johnson Surgical Vision, INC. | $2,557.29 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Glaukos Corporation | $899.96 | 2020-2025 | Radius, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Mallinckrodt Hospital Products INC. | $360.30 | 2021-2024 | Acthar |
| Allergan, INC. | $350.73 | 2019-2021 | |
| Harrow Eye, LLC | $296.06 | 2025 | |
| Dompe US, INC. | $285.03 | 2021-2025 | Oxervate |
| New World Medical,INC. | $280.26 | 2022-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Novartis Pharmaceuticals Corporation | $212.04 | 2019-2022 | |
| Rxsight INC | $210.18 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $207.55 | 2019-2021 | |
| Abbvie INC. | $173.39 | 2025 | |
| Sight Sciences, INC. | $167.09 | 2022 | |
| Aerie Pharmaceuticals, INC. | $151.36 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $148.56 | 2022-2025 | Cequa |
| Astellas Pharma US INC | $125.33 | 2025 | Izervay |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Staar Surgical Company | $64.68 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $61.80 | 2021 | |
| Rayner Intraocular Lenses Limited | $42.80 | 2023-2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Bausch & Lomb Americas INC. | $41.34 | 2023-2024 | Xiidra, Miebo |
| Oyster Point Pharma, INC. | $27.27 | 2022 | |
| Amgen INC. | $26.68 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $24.34 | 2025 | Xdemvy |
| Thea Pharma INC. | $22.35 | 2023 | Iyuzeh |
| Iridex Corporation | $17.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.